News | June 03, 2021
Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Aurobindo has one of the most enduring generics ecosystems among peers
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
7.94 crore doses were made available to the states in May 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
